Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.

Voysey M. et al, (2023), Clin Exp Immunol, 211, 280 - 287

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.

Mentzer AJ. et al, (2023), Nat Med, 29, 147 - 157

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.

Madhavan M. et al, (2022), EBioMedicine

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.

Marchevsky NG. et al, (2022), EBioMedicine, 81

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.

Li G. et al, (2022), Lancet, 399, 2212 - 2225

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.

Sharpe HR. et al, (2022), JCI Insight, 7

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Tomic A. et al, (2022), Nat Commun, 13

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15

Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS).

Butler C. et al, (2021), Vaccines (Basel), 9

Antibody evasion by the P.1 strain of SARS-CoV-2.

Dejnirattisai W. et al, (2021), Cell, 184, 2939 - 2954.e9

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.

Datoo MS. et al, (2021), Lancet, 397, 1809 - 1818

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.

Zhou D. et al, (2021), Cell, 184, 2348 - 2361.e6

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.

Supasa P. et al, (2021), Cell, 184, 2201 - 2211.e7

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies.

Folegatti PM. et al, (2021), Vaccines (Basel), 9

Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.

van Doremalen N. et al, (2021), Nature, 590

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.

van Doremalen N. et al, (2020), Nature, 586, 578 - 582

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (vol 396, pg 467, 2020)

Folegatti PM. et al, (2020), LANCET, 396, 466 - 466

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Folegatti PM. et al, (2020), Lancet, 396, 467 - 478

Safety and Immunogenicity of a candidate MERS-CoV Viral Vectored Vaccine: a phase I, open-labelled, first-in-human, dose-escalation trial.

GILBERT S. et al, (2020), Lancet Infectious Diseases

Include forthcoming?